Abstract 917P
Background
Patients with oral cavity squamous cell carcinoma (OCSCC) are at high risk of death within 5 years of treatment. Previous works have demonstrated that spatial arrangement of tumor-infiltrating lymphocytes (TILs) and surrounding nuclei (e.g, cancer nuclei, macrophages, fibroblasts) is prognostic of overall survival (OS) in different types of cancer, including oropharyngeal and laryngeal. In this work, we evaluated the prognostic ability of a computerized strategy that characterizes the spatial arrangement of TILs & non-TILs on digitized H&E-stained slides of patients with OCSCC.
Methods
Whole slide images (WSIs) from a cohort of 283 patients with OCSCC were retrospectively collected from the Cancer Genome Atlas (TCGA, D1). Additionally, WSIs from 136 patients with OCSCC were obtained from Vanderbilt University Medical Center (VUMC, D2). D1 was used to train a prognostic model while D2 was used for independent validation. Computer algorithms automatically identified 2 types of nuclei (TILs & non-TILs) and built clusters for each nucleus type based on proximity. Metrics related to density, intersection, and neighborhood were computed from these clusters. A proportional hazard Cox regression model, regularized via the least absolute shrinkage and selection operator, was trained to predict risk of death. The percentile 66 risk score on D1 was used as a threshold for stratifying patients on D2 as either low or high risk. Survival analysis was then used to evaluate the association with OS.
Results
Patients in D2 defined as “low risk” (57%) based on spatial arrangement of TILs has significantly better OS than those identified as “high risk” (43%) with hazard ratio=3.84 (95% confidence interval: 1.39-10.6, p<0.01). Multivariable survival analysis showed that this model was prognostic independent of age and overall, T, and N stages with HR=2.88 (95% CI: 1.10-7.56, p=0.03).
Conclusions
A computerized image analysis model based on measurements of spatial arrangement of TILs & non-TILs was found to be prognostic in patients with OCSCC. With more modeling and development, this model may provide a risk classifier for use in routine clinical practice.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
A. Madabhushi.
Funding
US National Institutes of Health, US Department of Defense.
Disclosure
A. Madabhushi: Financial Interests, Personal, Advisory Board, Serve on SAB and consult: SimbioSys; Financial Interests, Personal, Advisory Board: Aiforia, Picture Health; Financial Interests, Personal, Full or part-time Employment: Picture Health; Financial Interests, Personal, Ownership Interest: Picture Health, Elucid Bioimaging, Inspirata Inc; Financial Interests, Personal, Royalties: Picture Health, Elucid Bioimaging; Financial Interests, Institutional, Funding: AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly. All other authors have declared no conflicts of interest.
Resources from the same session
1025P - Fully intravenous delivery regimen of oncolytic adenovirus coding for TNFa and IL-2 (TILT-123) in patients with advanced solid cancers
Presenter: Santeri Pakola
Session: Poster session 03
1026P - Updated results from the phase I 1456-0001 study for intratumoral (IT) VSV-GP (BI 1831169) in patients with advanced solid tumors
Presenter: Stephane Champiat
Session: Poster session 03
1027P - First results for intravenous (IV) VSV-GP (BI 1831169) in patients (pts) with advanced solid tumors from the 1456-0001 study
Presenter: Marc Oliva Bernal
Session: Poster session 03
1028P - A phase I study of personalized KSX01-TCRT therapy for advanced solid tumor and its mechanisms
Presenter: Shuhang Wang
Session: Poster session 03
Resources:
Abstract
1029P - Preclinical development of TCR-modified T cell therapies against mutated KRAS
Presenter: Hugh Salter
Session: Poster session 03
1030P - Survival rates in high-risk neuroblastoma patients undergoing anti-GD2 immunotherapy: A single arm meta-analysis and systemic review
Presenter: Lorena Escalante Romero
Session: Poster session 03
1032P - Tumor-infiltrating lymphocytes with inducible membrane-tethered IL-12 cultured in optimized media exhibits superior anti-tumor activity
Presenter: Patrick Innamarato
Session: Poster session 03
1033P - Anti-tumor efficacy and safety of conditionally activated armored CAR-T cells against gastrointestinal tumors
Presenter: Zhihong Huang
Session: Poster session 03
1034P - Preclinical development of genetically modified tumor-infiltrating lymphocytes using biopsy samples from liver cancer patients
Presenter: Mingyu Liu
Session: Poster session 03
1035P - A new IL-6 inducing mechanism in cancer with new therapeutic possibilities
Presenter: Leif Håkansson
Session: Poster session 03